Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

joins Seana Smith and Brad Smith on Morning Brief to discuss her outlook for the GLP-1 market in 2025: "In terms of the inflection point for the market, you know, both Novo Nordisk (NVO ...

The latest move by Novo Nordisk follows Eli Lilly's earlier petition against the inclusion of certain GLP-1 receptor agonists in the 503B list.

Coming off of Novo Nordisk's (NVO) sharp stock decline after ... which is their small molecule pill GLP-1, which could really open up the market. So I feel like Novo is kind of losing its pep ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

Novo Nordisk wins hard-fought FDA approval ... some lessons from Novo and Lilly's efforts. Up-and-coming GLP-1 players whose products could start trickling onto the market around 2026 will likely ...

Coming off of Novo ... products for both Lilly and Novo," BMO Capital Markets managing director of biopharma equity research Evan Seigerman explains. "And then mid-year for Lilly, we have Orforglipron ...

As concerns around knockoffs of newer GLP-1 drugs like Ozempic and Wegovy take center stage, Novo Nordisk’s efforts ... and quality standards as the Lilly products they reference.

Globally, Novo Nordisk holds 65% of the market for GLP-1 medicines by volume ... all-important competitive fight against Eli Lilly's products. Aside from the major issue of CagriSema's efficacy ...